Crossmark

Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

Crossref DOI link: https://doi.org/10.1186/s12913-018-3398-x

Published Online: 2018-08-02

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lorenzoni, Valentina

Triulzi, Isotta

Turchetti, Giuseppe https://orcid.org/0000-0002-1877-5459
Funding

Funding for this research was provided by:

Swedish Orphan Biovitrum (SOBI) Italia
License Information

Text and Data Mining valid from 2018-08-02
More Information

Article History

Received: 14 June 2017

Accepted: 15 July 2018

First Online: 2 August 2018

Ethics approval and consent to participate

: Not applicable

: Not applicable

: VL, IT and GT declare that they have no conflict of interest. SOBI is not financed by Bioverativ; SOBI has entered into a commercialization partnership agreement with Bioverativ which manufactures Elocta/te for both SOBI and Bioverativ.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below